Kovivac

Russia has approved its third vaccine, developed by the Chumakov Federal Scientific Center for Research and Development of Biological and Immune Products of the Russian Academy of Sciences. The vaccine was due to start being administered in the second half of March, although as of 25 March it had not yet been used to immunise the population.

It is a virus inactivated vaccine, that consists of the inoculation of a dead version of the virus able to trigger an immune response, but not being able to cause the disease. The vaccine has not yet started phase III of the clinical trials. In the first two, which started in September 2020, a total of 600 volunteers participated. 

The injection will be administered in two doses separated 14 days each other, and are stored at a temperature between 2º and 8ºC, as Deputy Prime Minister Tatiana Golikova informed in a press release in January. She there assured that the vaccine is completely sure and the majority of volunteers developed a stable immunity after 28 days, without specifying the efficacy. There are no published results yet.